MX2020006942A - Dominios ck y ch1 modificados. - Google Patents

Dominios ck y ch1 modificados.

Info

Publication number
MX2020006942A
MX2020006942A MX2020006942A MX2020006942A MX2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A MX 2020006942 A MX2020006942 A MX 2020006942A
Authority
MX
Mexico
Prior art keywords
cîo
domains
modified
pairing
antigen
Prior art date
Application number
MX2020006942A
Other languages
English (en)
Inventor
Yongqiang Wang
Lei Fang
Zhengyi Wang
Bingshi Guo
Jingwu Zang
Original Assignee
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd filed Critical I Mab Biopharma Us Ltd
Publication of MX2020006942A publication Critical patent/MX2020006942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporcionan anticuerpos y fragmentos de unión a antígeno con los dominios C? y CH1 modificados que aún permiten el emparejamiento de los dominios C? y CH1, pero que tienen emparejamiento reducido con los dominios C? y CH1 de tipo silvestre sin las modificaciones. Dichas modificaciones pueden ser particularmente útiles para preparar anticuerpos biespecíficos con dos pares diferentes de dominios C? y CH1.
MX2020006942A 2018-01-15 2019-01-15 Dominios ck y ch1 modificados. MX2020006942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018072564 2018-01-15
PCT/CN2019/071740 WO2019137552A1 (en) 2018-01-15 2019-01-15 MODIFIED Cκ AND CH1 DOMAINS

Publications (1)

Publication Number Publication Date
MX2020006942A true MX2020006942A (es) 2020-09-14

Family

ID=67219407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006942A MX2020006942A (es) 2018-01-15 2019-01-15 Dominios ck y ch1 modificados.

Country Status (14)

Country Link
US (1) US20190389972A1 (es)
EP (1) EP3577141A4 (es)
JP (1) JP6996825B2 (es)
KR (1) KR102471868B1 (es)
CN (1) CN110573531B (es)
AU (2) AU2019203917B2 (es)
BR (1) BR112020009414A2 (es)
CA (1) CA3084398A1 (es)
EA (1) EA202091053A1 (es)
IL (1) IL275943B (es)
MX (1) MX2020006942A (es)
SG (1) SG11202005009RA (es)
WO (1) WO2019137552A1 (es)
ZA (1) ZA202002567B (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CN104797599A (zh) * 2012-11-05 2015-07-22 全药工业株式会社 抗体或抗体组合物的制备方法
WO2014150973A1 (en) * 2013-03-15 2014-09-25 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3143043B1 (en) * 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
EP3107938B1 (en) * 2014-05-28 2022-05-04 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
MX2017006250A (es) * 2014-11-14 2017-11-17 Hoffmann La Roche Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf.
JP7239320B2 (ja) * 2015-10-02 2023-03-14 エフ． ホフマン－ラ ロシュ アーゲー 多重特異性抗体
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
CN115920030A (zh) * 2015-12-09 2023-04-07 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
JP2019503172A (ja) * 2015-12-28 2019-02-07 マサチューセッツ インスティテュート オブ テクノロジー 定常領域の変異を有する二重特異性抗体およびその使用
KR102361412B1 (ko) * 2016-03-25 2022-02-09 바이오뮤넥스 파마슈티컬스 Cd38 및 pd-l1에 대한 결합 분자

Also Published As

Publication number Publication date
ZA202002567B (en) 2021-04-28
AU2020203065B2 (en) 2023-04-06
AU2020203065A1 (en) 2020-05-28
CN110573531B (zh) 2021-04-02
EP3577141A1 (en) 2019-12-11
BR112020009414A2 (pt) 2020-11-03
KR20200059186A (ko) 2020-05-28
AU2019203917A1 (en) 2019-08-01
EA202091053A1 (ru) 2020-12-03
AU2019203917B2 (en) 2020-04-02
IL275943B (en) 2022-06-01
US20190389972A1 (en) 2019-12-26
IL275943A (en) 2020-08-31
CN110573531A (zh) 2019-12-13
CA3084398A1 (en) 2019-07-18
WO2019137552A1 (en) 2019-07-18
JP2021506747A (ja) 2021-02-22
JP6996825B2 (ja) 2022-01-17
SG11202005009RA (en) 2020-06-29
KR102471868B1 (ko) 2022-11-30
EP3577141A4 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
PH12019502283A1 (en) Anti-lag3 antibodies
MX2022002364A (es) Anticuerpos anti-pd-l1.
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
JOP20200309A1 (ar) أجسام مضادة لـ il-11
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
NI201400019A (es) Anticuerpo anti-alfabetatcr
MX353278B (es) Raton con cadena ligera comun.
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2019011585A (es) Anticuerpos miltiespecificos estables.
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
MX2021010893A (es) Anticuerpo biespecifico enlazado especificamente a vegf y ang2.
GEP20217311B (en) High affinity and aggregatively stable antibodies on basis of variable domains vl and derivative vhh
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2020011614A (es) Anticuerpos con perfiles de glicanos modulados.
MX2020006942A (es) Dominios ck y ch1 modificados.
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
MX2021007369A (es) Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3.